Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598733 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL4430217 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL13598781 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL14440600 | 0.92 | ADORA2A (0.47) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL1740552 | 0.89 | ADORA2A (0.43) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL18661709 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL18661710 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL12219557 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL12194659 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL16311924 | 0.87 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| EP-1539188-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK SHARP & DOHME (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-1476169-B1 | Inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| EP-2399588-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1707571-B1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20040259934-A1 | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds | OLSEN DAVID B (US) | 2004-12-23 | — | — | US | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| CN-1498221-A | Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase | — | 2004-05-19 | — | — | CN | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| WO-2004028481-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADORA3 334/4885ADORA1 550/4885 |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | RNASEH1, RNASE1, RNASEL | ADORA2A 1134/4885ADORA3 649/4885ADORA1 735/4885 |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADORA3 170/4885ADORA1 522/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | ADORA2A 813/4885ADORA3 464/4885ADORA1 539/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 395/4885ADORA3 304/4885ADORA1 493/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | ADORA2A 1654/4885ADORA3 742/4885ADORA1 1401/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADORA3 334/4885ADORA1 550/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADORA3 334/4885ADORA1 550/4885 |
| US-20040259934-A1 | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds | SARS1, ACE, ACE2 | ADORA2A 421/4885ADORA3 401/4885ADORA1 381/4885 |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADORA3 334/4885ADORA1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.